Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

B. Natale, Ronald; Thongprasert, Sumitra; Anthony Greco, F.; Thomas, Michael; Tsai, Chun‐Ming; Sunpaweravong, Patrapim; Ferry, David; Mulatero, C; C. Whorf, Robert; Thompson, Joyce; Barlési, Fabrice; Langmuir, Peter; Gogov, Sven; Rowbottom, Jacqui; Goss, Glenwood

doi:10.1200/jco.2010.28.5981

Public

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Feb 1, 2011

Authors:

Ronald B. Natale

Sumitra Thongprasert

F. Anthony Greco

Abstract

PURPOSE: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This phase III study assessed the efficacy of vandetanib versus erlotinib in unselected patients with advanced non-small-cell lung cancer (NSCLC) after tr...

Subject

Vandetanib

Erlotinib

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!